CStone and Pfizer will develop late-stage oncology therapies in China. Credit: National Cancer Institute on Unsplash.

CStone Pharmaceuticals has completed the previously announced share subscription agreement through which a Pfizer affiliate subscribed for newly issued CStone shares at around $200m.

In September, CStone entered a multifaceted strategic partnership with Pfizer to develop and commercialise late-stage oncology therapies in China.

Hong Kong’s Listing Committee of the Stock Exchange  approved the listing of 115,928,803 additional shares subscribed by Pfizer at around HK$13.37 ($1.725) per share.

Pfizer now owns almost 9.9% of stake in CStone.

The deal will extend financing to develop and commercialise CStone’s sugemalimab, an investigational anti-PD-L1 monoclonal antibody for high-incidence cancers, including lung, gastric and oesophageal cancers, among others.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Sugemalimab imitates the natural G-type immunoglobulin 4 (IgG4) human antibody and thereby reduces immunogenicity and toxicity risks in patients.

The drug has completed a Phase I dose-escalation study in China and demonstrated antitumor activity in multiple tumour types in the Phase Ia and Ib trials.

As part of the agreement, Pfizer will get an exclusive licence to commercialise the drug candidate in mainland China.

The companies will develop and commercialise additional oncology assets in the Greater China market.

They may also pursue on a selected basis joint in-licensing set up for these assets.

At the time of signing the agreement, Pfizer Biopharmaceuticals Group China acting president Pierre Gaudreault said: “This collaboration with CStone builds on that history by helping to develop a potential best-in-class PD-L1 treatment that we can commercialise upon approval.”

Clifford Chance was the legal advisor for Pfizer. Goldman Sachs acted as financial advisor for CStone while Cooley LLP served as legal advisor.